Research on the Elucidation of the Prognostic Factor and Mechanism of Drug Resistance in Gastric Cancer Patients who Receive Systemic Chemotherapy.

Research on the Elucidation of the Prognostic Factor and Mechanism of Drug Resistance in Gastric Cancer Patients who Receive Systemic Chemotherapy. - Biomarker Study in Gastric Cancer Patients with Primary Lesion.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009564

Enrollment

200

Registered

2012-12-17

Start date

2012-12-20

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer patients with primary lesion.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Equal to or over 20 years. 2.Established diagnosis of typical gastric cancer by histology or cytology. 3.Target lesion(at least one lesion) are detected by diagnostic imaing performed within 4 weeks. 4.Patient who is planned to receive systemic chemotherapy for advanced gastric cancer. 5.Patient who is planned to evaluate the expression of HER2. 6.Written informed concent can be obtained.

Exclusion criteria

Exclusion criteria: 1.Patients who need continuous anti- coaglant therapy (impossible to stop anti-coaglant therapy). 2.Patients who are considered to be ineligible by referring physician.

Design outcomes

Primary

Measure	Time frame
Identification of prognostic factors which correlate with tumor response.	—

Secondary

Measure	Time frame
Identification of prognostic factors which correlate with survival. Identification of biomarkers which correlate with drug resistance.	—

Countries

Japan

Contacts

Public ContactYoshitaka Honma

National Cancer Center Hospital in Japan Department of Gastrointestinal Oncology

yohonma@ncc.go.jp03-3542-2511

Outcome results